Hepatitis Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
Investigators at MOGAM Biotechnology Research Institute have published new data on gene therapy
July 9th, 2007
Data detailed in "Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I" have been presented. "Tissue-targeted delivery of small interfering RNA (siRNA) must be achieved before RNA interference (RNAi) technology can be used in practical therapeutic approaches. In this study, the potential of apolipoprotein A-I (apo A-I) for the systemic delivery of nucleic acids to the liver is demonstrated using real-time in vivo imaging," scientists writing in the journal Molecular Therapy report. "As a proof of concept, synthetic siRNAs against hepatitis B virus (HBV) were formulated into complexes of apo A-I and...
Source: Hepatitis Weekly (2007-07-09)
|
